doxazosin has been researched along with Cirrhosis in 4 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To gain new insights into the molecular mechanisms of action of doxazosin, we investigated the prostatic stroma ultrastructure and the expression of genes involved with fibrosis, such as collagen type I and III (COL1A1 and COL3A1, respectively) and TGF-beta 1, in the rat ventral prostate." | 7.78 | Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment. ( Almeida, FL; Delella, FK; Felisbino, SL; Lacorte, LM; Pai, MD, 2012) |
| "Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men." | 5.30 | Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. ( Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS, 2019) |
| "To gain new insights into the molecular mechanisms of action of doxazosin, we investigated the prostatic stroma ultrastructure and the expression of genes involved with fibrosis, such as collagen type I and III (COL1A1 and COL3A1, respectively) and TGF-beta 1, in the rat ventral prostate." | 3.78 | Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment. ( Almeida, FL; Delella, FK; Felisbino, SL; Lacorte, LM; Pai, MD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Macoska, JA | 1 |
| Uchtmann, KS | 1 |
| Leverson, GE | 1 |
| McVary, KT | 1 |
| Ricke, WA | 1 |
| Delella, FK | 1 |
| Lacorte, LM | 1 |
| Almeida, FL | 1 |
| Pai, MD | 1 |
| Felisbino, SL | 1 |
| Perlini, S | 1 |
| Palladini, G | 1 |
| Ferrero, I | 1 |
| Tozzi, R | 1 |
| Fallarini, S | 1 |
| Facoetti, A | 1 |
| Nano, R | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Fogari, R | 1 |
| Ferrari, AU | 1 |
| Varagic, J | 1 |
| Susic, D | 1 |
| Frohlich, ED | 1 |
1 trial available for doxazosin and Cirrhosis
| Article | Year |
|---|---|
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disea | 2019 |
3 other studies available for doxazosin and Cirrhosis
| Article | Year |
|---|---|
Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Collagen Type I; Collagen Type I, alpha 1 Chain; C | 2012 |
Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiomegaly; Co | 2005 |
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2001 |